Sugi Predict

Sugi Predict / Targets / NUP205

NUP205

Nuclear pore complex protein Nup205 · Q92621 · NUP205 on Sugi Atlas →

0 patent compounds predicted against NUP205, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to NUP205 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men PHASE3ACTIVE_NOT_RECRUITING
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt) PHASE1/PHASE2RECRUITING
Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination PHASE1/PHASE2COMPLETED
A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas PHASE2COMPLETED
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma PHASE1WITHDRAWN
Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy PHASE1COMPLETED
Role of the Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections nanCOMPLETED
Molecular Genetics Study of Nasopharyngeal Carcinoma: Characterization of NCP Susceptibility Gene(s) nanCOMPLETED
Biomarker for Niemann Pick Type C Disease (BioNPC) nanWITHDRAWN
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C nanRECRUITING
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients nanRECRUITING
Family Study of Head and Neck Cancers in Taiwan nanCOMPLETED
A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy nanCOMPLETED
Quantitative Assessment of the Etiologies of Megalencephaly Associated With a Detectable Tumor Risk nanNOT_YET_RECRUITING
HCCBloodTest for Detection of Hepatocellular Carcinoma (HCC) nanCOMPLETED
Predictive Value of Maternal Blood Protein Signatures in Preterm Birth nanCOMPLETED
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome nanCOMPLETED
Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion nanRECRUITING
Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Sequencing nanNOT_YET_RECRUITING
Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging nanUNKNOWN
Classification, Functional Stratification and Biomarkers in Ciliopathy (CILLICORIRCM) nanCOMPLETED
Genetics of Neonatal Encephalopathy and Related Disorders nanRECRUITING
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis) nanCOMPLETED
Genetic Investigation of Solid Tumors Cohort nanCOMPLETED
Molecular Mechanism of Nasopharyngeal Carcinoma nanUNKNOWN
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a NUP205 binder may also engage these)

ProteinNameSimilarity
Q5T2E6 — 0.995 Q5T2E6 →
Q8IV36 — 0.995 Q8IV36 →
B1AY13 — 0.995 B1AY13 →
Q5F3M0 — 0.994 Q5F3M0 →
Q9Y3R5 — 0.994 Q9Y3R5 →
Q6DCT2 — 0.994 Q6DCT2 →
USP24 Ubiquitin carboxyl-terminal hydrolase 24 0.994 landscape →
Q99ML0 — 0.994 Q99ML0 →
Q6PD19 — 0.994 Q6PD19 →
Q5FWU8 — 0.993 Q5FWU8 →
O94915 — 0.993 O94915 →
Q6PGW3 — 0.993 Q6PGW3 →
Q24134 — 0.992 Q24134 →
A5GFY4 — 0.992 A5GFY4 →
F1QN74 — 0.992 F1QN74 →
Q99K74 — 0.992 Q99K74 →
Q9ESE1 — 0.992 Q9ESE1 →
Q6ZS30 — 0.992 Q6ZS30 →
Q2PW47 — 0.992 Q2PW47 →
FANCI Fanconi anemia group I protein 0.992 landscape →
Q3UHQ6 — 0.992 Q3UHQ6 →
Q80YV3 — 0.991 Q80YV3 →
F6WXT2 — 0.991 F6WXT2 →
O75800 — 0.991 O75800 →
P21359 — 0.990 P21359 →
Q5TBA9 — 0.990 Q5TBA9 →
E9Q8I9 — 0.990 E9Q8I9 →
Q9P2D8 — 0.989 Q9P2D8 →
Q4V8B3 — 0.989 Q4V8B3 →
Q8TEL6 — 0.989 Q8TEL6 →